IR Presentation template [SA, JA, sector]
|
|
- Randolph Dean
- 5 years ago
- Views:
Transcription
1 1 Biotechnology Industry IR Presentation template [SA, JA, sector] Healthcare Sector - Fall 2016 Senior Analyst: Austin Gasparini Junior Analysts: Donavon Young, Marlon Li, Josh Zins
2 Industry Definition and Key Players Biotechnology The exploitation of biological processes for industrial and other purposes Companies in this industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food and services that meet human needs AbbVie Inc. NYSE: ABBV Market Cap.: $101.48B Amgen Inc. NASDAQ: AMGN Market Cap.: $118.62B Gilead Sciences NASDAQ: GILD Market Cap.: $98.04B Monsanto Company NYSE: MON Market Cap.: $44.68B Biogen, Inc. NASDAQ: BIIB Market Cap.: $63.69B Celgene Corporation NASDQ: CELG Market Cap.: $76.67B Sources: IBISWorld, S&P Global Equity Research Report March
3 Industry Summary Key Facts Life Cycle: Growth Revenue: $108.8bn Profit: $9.8bn Genentech, Major Companies Monsanto, Other, Annual Growth: (11-16 ) = 1.79% (16-21e ) = 4.11% Characteristics: Low revenue volatility Medium capital intensity High competition AbbVie, Amgen, Gilead, Industry Rating: POSITIVE Aging US population drives growth in human health technologies Pharmaceuticals remains the largest market for biotechnology companies Specialty drug costs continue to rise Oncology spending keeps increasing Sources: IBISWorld, FiercePharma 3
4 Product Segmentation 8.6% Industrial technologies 11.7% Agricultural and aquacultural technologies Industry Products as a Percentage of Revenue 5.7% Environmental remediation and natural resource recovery 5.6% Animal health, marine and terrestrial microbial technologies 68.4% Human health technologies Human Health Technologies Biologic pharmaceuticals, pharmacogenomics, gene therapy, and gene testing Biologics are medicinal products (vaccines, somatic cells, blood and blood components, etc.) that are created by biological processes Agricultural and Aquacultural Technologies Genetic manipulation of a highly developed crop variety to impart yieldenhancing traits Soybeans, corn, cotton, and canola are the most modified crops Industrial Technologies A new approach to pollution prevention, resource conservation and cost reduction Companies use specialized techniques to find and improve enzymes based on their ability to assist industrial processes Environmental Remediation and Resource Recovery Application of life science and genetics research to manufacturing Enzyme-catalyzed processes are generally more efficient than chemical processes because input yields are higher and fewer steps are involved Animal health, marine and terrestrial microbial technologies Discovery and creation of therapeutic products (proteins, antibodies, enzymes), diagnostic tools and preventive measures Investigation of marine and terrestrial organisms with extreme adaptations Sources: IBISWorld 4
5 Value Chain Overview Discovery Development Manufacturing Sales Identification/ Validation Pre-clinical Trials Purification/ Formulation B2B/B2C Marketing Screening/ Optimization Clinical Trials Patent Application FDA Submission Sources: North Carolina in the Global Economy, S&P Global Equity Research Report March
6 Trend #1-Global Oncology Spending Fuels Revenue Growth 6 Global Oncology Spending Continues to Grow Specialty Drug Costs Outpace Inflation Aging U.S. Population
7 Trend #1-Global Oncology Spending Fuels Revenue Growth Revenue Number of Diagnoses $106 $104 $102 $100 $98 Correlation: Industry Revenue-Global Oncology Costs (US$BN) R² = $96 $80 $85 $90 $95 $100 $105 $110 Oncology Costs New Cancer Diagnoses Per Year in US 3,000,000 Cancer treatments comprise 44% of the biotechnology pipeline Global spending for cancer treatment reached $100 billion in 2014 Market for cancer drugs to reach $147 billion by 2018 Cancer is a disease of aging Further contributions include: 18% of US adults still use cigarettes, and obesity rates remain at approximately 33% 2,500,000 2,000,000 1,500,000 1,000, , Years Global cancer spending is projected to increase over the next 20 years, providing revenue growth opportunities throughout the industry Sources: IMS Institute Global Oncology Report 2015, Beyond Borders: Global Biotechnology Report 2014, IBISWorld, Cancer Progress Report 2015, NIDDK 2010 Report 7
8 Trend #2-Specialty Drug Costs Outpace Inflation 8 Global Oncology Spending Continues to Grow Specialty Drug Costs Outpace Inflation Aging U.S. Population
9 Trend #2-Specialty Drug Costs Outpace Inflation Spending PMPY Specialty Drug Spending Per Member Per Year (PMPY) $400 $300 $200 $100 $ Years Total Spending on the Top Specialty Drug Categories (2014) Specialty drugs represent ~33% of drug spending per member per year (PMPY) and account for <1% of drug prescriptions Three specialty classes (inflammatory conditions, multiple sclerosis, cancer) accounted for a majority of specialty spending in 2014 Rising cancer and Hepatitis C costs are primarily responsible HIV, Hepatitis, Other, Multiple Sclerosis, Cancer, Inflammator y Conditions, Specialty drugs account for ~33% of total drug spending PMPY despite accounting for <1% of drug prescriptions and costs continue to increase Sources: Specialty Drug Trends Reports , S&P Global Equity Research Report
10 Trend #3-Aging US Population 10 Global Oncology Spending Continues to Grow Specialty Drug Costs Outpace Inflation Aging U.S. Population
11 Trend #3-Aging US Population Population (millions) US Population Projections (in millions) % 16.1% 19.3% 20.0% 20.2% Years Age Distribution of Low vs. High Spending Groups >65 Years <65 Years Adults 65+ years old are growing both as a percentage of the total US population and as a total population in the US Result of the Baby Boomers that began turning 65 in 2011 Highest healthcare spenders are typically older and have chronic conditions Top 5% of healthcare spenders account for nearly 50% of healthcare spending 100% 4.1% 80% 60% 40% 20% 19.5% 41.8% 34.5% 38.2% 39.9% 38.3% 39.3% 17.2% 13.2% An aging population will increase overall healthcare spending, as a large portion of the highest healthcare spenders are aged 65+ 0% 6.3% 7.6% Lowest 50% Top 5% Top 1% Sources: CMS.gov, Administration for Community Living 2010 Report, An Aging Population: The Older Population in the United States 2014, National Institute for Healthcare Management 11
12 Industry Risks There are three major risk factors to the biotechnology industry: Negative Public Perception of the Drug Industry Various drug pricing scandals have dominated the news cycle (Epipen and Daraprim) Public outrage could fuel the passage of heavy regulations in retaliation Potential Reformation of the Food and Drug Administration The current President-elect has expressed a desire to reform the FDA in the future Drug and human health technology approval could be backlogged if reformation measures go through New approval pathway could be stricter and slower in the future Potential Reform of the U.S. Healthcare System With a Republican controlled government, there is a high likelihood of a repeal/replacement of Obamacare Loss of coverage for millions of Americans could result in significantly less prescription drug spending/healthcare spending in general Sources: FierceBiotech 12
13 13 CompCo Analysis Ticker Name Price 2 52-Week High NLNK NewLink Genetics Corp. 52-Week Low Equity Value Enterprise Value Debt/Equity EV/Sales Price/Sales $11.46 $38.92 $9.23 $ $ MGNX MacroGenics Inc. $27.48 $36.11 $14.84 $ $ ARRY Array BioPharma Inc. $8.23 $7.27 $2.38 $1, $1, AGEN Agenus Inc. $4.35 $7.49 $2.61 $ $ BLCM CLDX Bellicum Pharmaceuticals, Inc. Celldex Therapeutics Inc. 1 in millions of USD, except per share data 2 Prices as of 11/29/16 $19.16 $23.84 $7.24 $ $ $4.02 $18.62 $2.85 $ $ High (Excluding Outliers) 0.41x 23.61x Mean (Excluding Outliers) Median (Excluding Outliers) 76.51x 0.18x 11.68x 23.11x 0.15x 7.64x 9.36x Low (Excluding Outliers) 0.06x 5.11x 5.74x
14 14 Summary Recommendation Industry Rating POSITIVE Global Oncology Spending is Increasing New cancer diagnoses and cancer spending is projected to increase Provides revenue growth opportunity for biologic drug manufacturers Specialty Drug Costs are Significant and Rising Specialty drugs demand a premium price and constitute a larger and larger share of drug spending each year Most biologic drugs are specialty drugs Aging U.S. Population Spurs Healthcare Spending The percentage of adults aged 65+ is projected to grow continuously over the next few decades Healthcare spending increases significantly as people age
Primer: The Biotechnology Industry Han Zhong l September 2011
Primer: The Biotechnology Industry Han Zhong l September 2011 Introduction The budding biotechnology industry covers a wide range of human health biologic products and technologies that are created by
More informationBiopharmaceuticals February 8, 2017 Health Care - Biotechnology Industry Rating Market Weight
The Henry Fund Henry B. Tippie School of Management Aric Jensen [Aric-Jensen@uiowa.edu] Biopharmaceuticals February 8, 2017 Health Care - Biotechnology Industry Rating Market Weight Investment Thesis We
More informationNet Debt/EBITDA PEG EV/ Large-Cap Biotech (MM) (MM) LTM 2015E 2016E 2015E 2016E Book LTM NTM Unlevered FCF. Market Cap EV EV/EBITDA P/E Price/
To: From: Kelvin Li Danny Kim Date: August 18 th, 2015 Re: COMPANY DESCRIPTION Celgene Corporation (NYSE:CELG) COMPANY PROFILE INVESTMENT PROFILE Industry: Biotechnology Current (Proposed) Investment Size:
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationSpecialty Pharmacy 101
Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationBasic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.
APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health January 2018 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationManaging Your Drug Spend. Discussion Topics 8/10/2016. Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy
Managing Your Drug Spend Robert P. Navarro, PharmD Clinical Professor Department of Pharmaceutical Outcomes & Policy 2 Discussion Topics Introduction and overview Market conditions, expense centers, and
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationUndervalued Growth and Dividend Growth in Health Technology: Part 11
Undervalued Growth and Dividend Growth in Health Technology: Part 11 March 21, 2019 by Chuck Carnevale of F.A.S.T. Graphs Introduction Although many Health Technology Sector companies have significantly
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationBiotechnology Certificate New Technologies For Health
Weekly Barometer 25 janvier 2012 Biotechnology Certificate New Technologies For Health April 2017 ATONRÂ PARTNERS SA 12, Rue Pierre Fatio 1204 GENEVA SWITZERLAND - Tel: + 41 22 310 15 01 http://www.atonra.ch
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationHua Wang. Healthcare. Ran Zhang. Todd White. Simon Wu
Hua Wang Healthcare Ran Zhang Todd White Simon Wu Sector Overview Business and Economic Analysis Agenda Financial Analysis Recommenda
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationMolecular Biotechnology. Principles and applications of recombinant DNA
Molecular Biotechnology Principles and applications of recombinant DNA Chapter 1. The Molecular Biotechnology Revolution Science and Technology Science Search for knowledge Technology Practical of knowledge
More informationData Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski
Data Protection for Biologics: Balancing Innovation Incentives and Cost Savings Henry Grabowski Health Industry Forum Washington, DC June 11, 2009 What is Data Protection? Data protection is the period
More informationMARKET & BUSINESS INTELLIGENCE AND STRATEGY
MARKET & BUSINESS INTELLIGENCE AND STRATEGY HOW LARGE IS THE POTENTIAL MARKET? WHAT PRODUCTS WILL WE COMPETE WITH? WHO WILL BE THE NEW COMPETITION IN THE FUTURE? WHAT COMPETITIVE TACTICS WILL BE NEEDED?
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationOutlines Background Challenges Strategies Vision Opportunities
Biotechnology Challenges and Opportunities in Biotechnology Chris Pak, Ph.D. September 29, 2009 www.mtarget.com Outlines Background Challenges Strategies Vision Opportunities Biotechnology Any technological
More informationPresidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
More informationBB Biotech AG investing in leading science
BB Biotech AG investing in leading science SECA Conference, July 4 2018 Only for professional investors Dr. Daniel Koller, Head Portfolio Management, BB Biotech AG Caution regarding forward-looking statements
More informationAugust Green Biotechnology Peter Oakley Member of the Board of Executive Directors
August 2005 Green Biotechnology Peter Oakley Member of the Board of Executive Directors 1 Biotechnology & Markets 2 Focus of BASF Strategy 3 Research Platform 4 Business Model 5 Pipeline 6 Beyond Green
More informationTrump Biotech Special: A $7 Stock with Yuge Potential. Trump Biotech Special: A $7 Stock with Yuge Potential
Trump Biotech Special: A $7 Stock with Yuge Potential Xenon Pharmaceuticals: Vastly Undervalued With Yuge Potential It seems appropriate after all but secured the Republican nomination to highlight a small
More informationIT S WHAT YOU CAN T SEE THAT HURTS YOU IS THE PHARMACEUTICAL INDUSTRY REPLACING EXISTING MEDICATIONS WITH MORE EXPENSIVE MEDICATIONS?
SPECIALTY DRUGS Many plan sponsors have had to make difficult and painful choices about how to spend pharmacy benefit dollars But now payors are once again challenged not just by extremely high costs but
More informationGE Healthcare healthymagination Investor Update
GE Healthcare healthymagination Investor Update UBS John Dineen President & CEO, GE Healthcare May 6, 2011 "Results are preliminary and unaudited. This document contains forward-looking statements - that
More informationHealth Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center
Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center Dave Bode VP, Health Care Solutions DSC Logistics April 20, 2016 Health
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationGLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS
GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS BIO009G January 2017 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-417-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationMolecular Diagnostics: Market Segmentation and Opportunities
Molecular Diagnostics: Market Segmentation and Opportunities October 2010 This market report is published by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any form
More informationInsights into Rare Disease Drug Approval: Trends and Recent Developments
Insights into Rare Disease Drug Approval: Trends and Recent Developments Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough Summit
More informationEvolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors
HEALTHCARE Evolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors By Melissa Zebrowski Table of Contents Melissa Zebrowski Melissa Zebrowski has seven years of experience
More informationThe Challenges of [high-throughput] Phenotyping
The Challenges of [high-throughput] Phenotyping Mount Hood - sept 2008 Topics Introducing BASF Plant Science Phenotyping, for what purposes? What are the challenges? High-throughput phenotyping The TraitMill
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationDelivering on the Promise of Precision Medicine
Delivering on the Promise of Precision Medicine Bay Area Council Economic Institute Spring 2016 The Promise of Precision Medicine The Bay Area is one of the world s biggest hubs for innovation in research
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationMcKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationPersonalized healthcare Getting from promise to reality
Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationTRIANNI Media Kit MEDIA CONTACT CORPORATE HEADQUARTERS. Trianni, Inc. San Francisco, CA
TRIANNI Media Kit CORPORATE HEADQUARTERS Trianni, Inc. San Francisco, CA Telephone: 1.866.374.9314 MEDIA CONTACT Mandy Boyd Director of Marketing @Trianni_mAb Website: Trianni.com TECHNOLOGY LEADERSHIP
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationPharmacy Benefit Management: Strategies and Approaches for Managing Prescription Drug Costs
Pharmacy Benefit Management: Strategies and Approaches for Managing Prescription Drug Costs Adrian Washington PharmD., MBA Vice President of Client Management UnitedHealthcare / OptumRx Agenda 1. Discuss
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationThe Economic Contributions of the Biotechnology Industry to the U.S. Economy
The Economic Contributions of the Biotechnology Industry to the U.S. Economy Prepared for the Biotechnology Industry Organization by (UQVW
More informationProhost Letter #403 DECEMBER 14, Stories, Statements and Observations
Prohost Letter #403 DECEMBER 14, 2016 Stories, Statements and Observations On December 8, 2016 under News & Comments Prohost commented on President Elect Trump s statement that he is going to bring down
More informationClinical Supply Packaging for Biological Products
Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply
More informationPerspectives on BioPharma Innovation
Perspectives on BioPharma Innovation David Thomas, CFA Senior Director, Industry Research & Policy Analysis BIO Presented to members of the National Conference of State Legislatures June 2016 BIOTECHNOLOGY
More informationWhat is MTSL & BioInvest!
Biotech Investing Catch The Next Big Wave! John McCamant Editor, Medical Technology Stock Letter What is MTSL & BioInvest! The Medical Technology Stock Letter is your best tool for investing in Biotech
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationGlobal Gene Therapy Market Report -2026
Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic
More informationBASF Plant Science crop productivity from an industry perspective How to translate basic findings to improve crop productivity? BASF Plant Science
1 crop productivity from an industry perspective How to translate basic findings to improve crop productivity? EPSO Workshop Ghent, September 7-8th 2009 Dr. Jürgen Logemann VP Productivity needs to double
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 17th December 2015 Karl Branzén Sweden has experienced the winds of change in the drug industry u In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationProfessor Jane Farrar School of Genetics & Microbiology, TCD.
Lecture 1 Genetics An Overview Professor Jane Farrar School of Genetics & Microbiology, TCD. CAMPBELL BIOLOGY Campbell, Reece and Mitchell CONCEPTS OF GENTICS Klug and Cummings A Whistle-Stop Tour of 150
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationDr. Gary Mumaugh. DNA Technology
Dr. Gary Mumaugh DNA Technology Genetic Engineering Recombinant DNA Technology Times Recombinant DNA Production Recombinant DNA Applications Recombinant DNA Usages Recombinant DNA Social Considerations
More informationWorld s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for
Table of Contents SCOPE AND METHODOLOGY... 8 Market Definition... 8 Market Scope... 8 Market Stakeholders... 9 Research Methodology... 10 Secondary and Primary Research Methodology... 10 Market Size Estimation
More informationWebinar: Knowledge-based approaches to decreasing clinical attrition rates
Webinar: Knowledge-based approaches to decreasing clinical attrition rates Speakers: Dr. Richard K. Harrison Gavin Coney Teresa Fishburne May 2018 2 Clarivate Analytics is the global leader in providing
More informationBusiness and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE
Business and Industry Advisory Committee to the OECD - Comité Consultatif Economique et Industriel Auprès de l OCDE In Committee BIOTECHNOLOGY: A KEY CONTRIBUTOR TO SUSTAINABLE ECONOMIC GROWTH A Vision
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationPhRMA. Annual Press Conference
PhRMA Annual Press Conference February 1, 2017 Patrik Jonsson Chairman of Japan Based Executive Committee PhRMA Japanese Policy Changes Have Fostered Patients' Access to New Medicines Thanks to the transformation
More informationSection I: Creating a more Transparent and Predictable Environment for Innovation to Continue Improving People s Health Worldwide
SUPPLEMENT on HEALTHCARE INNOVATION 54th U.S.-Japan Business Conference The U.S.-Japan Business Council / Japan-U.S. Business Council November 3, 2017 Executive Summary Section I: Creating a more Transparent
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationPresentation at National Academy of Sciences -- Monday, November 14, 2016
Prescription Drug Spending in the U.S.: Is the Era of Slow Growth Over? An Update of an Article with the Same Title in the September 2016 issue of Health Affairs by Murray L. Aitken 1, Ernst R. Berndt
More informationPharmacy Benefit Management (PBM) Overview
Pharmacy Benefit Management (PBM) Overview Agenda Introductions to ARMSRx Team & Services Stephanie Cormier Christine Heutinck The PBM history and role in healthcare CIS key performance indicators (KPIs)
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationOrganizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito.
PhD Programme in Medicines and Pharmaceutical Innovation Course BioPharmaceuticals and Advanced Therapies Lisbon, 18, 19, 20 and 25, 26 September 2017 Faculty of Pharmacy Amphitheatre B Universidade de
More informationGuide to Valuation of Pharmaceutical Licensing Deals
Guide to Valuation of Pharmaceutical Licensing Deals Edited by Taskin Ahmed and Heather Cartwright SYNDICATED ANALYTICS PHARMADEALS Contents 1 Introduction... 7 1.1 Dealmaking in the Pharmaceutical Industry...
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationKey Findings From A National Survey Of Voters
Key Findings From A National Survey Of Voters Methodology On behalf of the Biotechnology Industry Organization (BIO), Public Opinion Strategies and Hart Research Associates conducted a national survey
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationOctober Nasdaq (CGIX) A Leader in Precision Oncology. Nasdaq (CGIX)
October 2018 Nasdaq (CGIX) A Leader in Precision Oncology Nasdaq (CGIX) Disclaimer These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationChina and India have demonstrated their capability in good
JACOBSEN I am one of the youngest managers at NNE and I believe one of the reasons for this is how I have been able to learn and expand to keep up with how fast automation is growing. DOR Building a great
More informationACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT
ACRUX (ACR) - ASX ANNOUNCEMENT 24 JULY 2017 ACRUX PRESENTS AT BIOSHARES BIOTECH SUMMIT Acrux (ASX: ACR) today announced that CEO and Managing Director, Michael Kotsanis presented at the 2017 Bioshares
More informationINDUSTRY OVERVIEW BIOLOGICS MARKET GLOBALLY AND IN CHINA. Definition of Biologics
Certain information and statistics set out in this section and elsewhere in this Document relating to the industry in which we operate are derived from the industry report prepared by Frost & Sullivan,
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More information